ReviewWorld journal of diabetes2021
Anti-diabetics and antimicrobials: Harmony of mutual interplay.
Review in World journal of diabetes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 48 citations in OpenAlex.
- Effects of empagliflozin and metformin on biofilm formation and pathogenicity factors of urinary Escherichia coli isolates.Folia microbiologica · 2026Article
- Metformin as a Metabolic Reprogramming Interface in Host-Pathogen and Bone Microenvironment Crosstalk: A Dual-Target Strategy Against Antimicrobial Resistance and Osteoporotic Bone Loss.Antibiotics (Basel, Switzerland) · 2026Review
- Empagliflozin modulates biofilm formation and virulence-associated gene expression in multidrug-resistant Staphylococcus aureus and Acinetobacter baumannii.Archives of microbiology · 2026Article
- Metformin as an Adjunct in Periodontal Therapy: Mechanistic Insights, Research Evidence and Current Challenges.Therapeutic innovation & regulatory science · 2026Review
- Enhanced meropenem activity and stability following load in Polyvinyl alcohol nanofiber scaffolds with sitagliptin as quorum sensing inhibitor on Pseudomonas aeruginosa.Journal of biological engineering · 2025Article
- From Control to Cure: Insights into the Synergy of Glycemic and Antibiotic Management in Modulating the Severity and Outcomes of Diabetic Foot Ulcers.International journal of molecular sciences · 2025Review
- Therapeutic efficacy ofFrontiers in nutrition · 2025Review
- Review
- Genome-wide identification, and gene expression analysis of NBS-LRR domain containing R genes inPhysiology and molecular biology of plants : an international journal of functional plant biology · 2024Article
- Modulating the antibacterial effect of the existing antibiotics along with repurposing drug metformin.Archives of microbiology · 2024Article
- Aconitum lycoctonum L. (Ranunculaceae) mediated biogenic synthesis of silver nanoparticles as potential antioxidant, anti-inflammatory, antimicrobial and antidiabetic agents.BMC chemistry · 2023Article
- Relocating Glyceryl Trinitrate as an Anti-Virulence Agent againstMicroorganisms · 2023Article
- Crippling of Klebsiella pneumoniae virulence by metformin, N-acetylcysteine and secnidazole.BMC microbiology · 2023Article
- Optimization of Potential Nanoemulgels for Boosting Transdermal Glimepiride Delivery and Upgrading Its Anti-Diabetic Activity.Gels (Basel, Switzerland) · 2023Article
- What's old is new again: Insights into diabetic foot microbiome.World journal of diabetes · 2023Review
- Drug repositioning: doxazosin attenuates the virulence factors and biofilm formation in Gram-negative bacteria.Applied microbiology and biotechnology · 2023Article
- Resistance, Tolerance, Virulence and Bacterial Pathogen Fitness-Current State and Envisioned Solutions for the Near Future.Pathogens (Basel, Switzerland) · 2023Review
- Synergistic Benefits: Exploring the Anti-Virulence Effects of Metformin/Vildagliptin Antidiabetic Combination againstBiomedicines · 2023Article
- Antibiotic susceptibility pattern, risk factors, and prediction of carbapenem-resistantHeliyon · 2023Article
- Diminishing the Pathogenesis of the Food-Borne PathogenBiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes is one of the four major non-communicable diseases, and appointed by the world health organization as the seventh leading cause of death worldwide. The scientists have turned over every rock in the corners of medical sciences in order to come up with better understanding and hence more effective treatments of diabetes. The continuous research on the subject has elucidated the role of immune disorders and inflammation as definitive factors in the trajectory of diabetes, assuring that blood glucose adjustments would result in a relief in the systemic stress leading to minimizing inflammation. On a parallel basis, microbial infections usually take advantage of immunity disorders and propagate creating a pro-inflammatory environment, all of which can be reversed by antimicrobial treatment. Standing at the crossroads between diabetes, immunity and infection, we aim in this review at projecting the interplay between immunity and diabetes, shedding the light on the overlapping playgrounds for the activity of some antimicrobial and anti-diabetic agents. Furthermore, we focused on the anti-diabetic drugs that can confer antimicrobial or anti-virulence activities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.